Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

CDXS
Codexis, Inc.
stock NASDAQ

At Close
Jan 7, 2026 3:59:55 PM EST
1.70USD-1.163%(-0.02)634,076
1.47Bid   1.97Ask   0.50Spread
Pre-market
Jan 7, 2026 9:11:30 AM EST
1.75USD+1.744%(+0.03)3,057
After-hours
Jan 6, 2026 4:37:30 PM EST
1.72USD+0.292%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 24, 2022
08:06AM EST  Codexis Announces FDA Orphan Drug And Rare Pediatric Disease Designations For CDX 6512 For Treatment of Homocystinuria   Benzinga
08:00AM EST  Codexis Announces FDA Orphan Drug and Rare Pediatric Disease   GlobeNewswire Inc
Jan 5, 2022
08:00AM EST  Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.   GlobeNewswire Inc
Dec 15, 2021
08:05AM EST  Codexis Highlights Launch Of Codex HiTemp Reverse Transcriptase To Address Key Challenges To 1-Step Assays For RNA Detection In PCR Testing, Including COVID-19   Benzinga
08:00AM EST  Codexis Launches Codex HiTemp Reverse Transcriptase to   GlobeNewswire Inc
Nov 22, 2021
08:23AM EST  Codexis Presents Pre-Clinical Data Highlighting Programs In Homocystinuria And Maple Syrup Urine Disease At ICIEM 2021   Benzinga
08:00AM EST  Codexis Presents Pre-Clinical Data Highlighting its Programs in   GlobeNewswire Inc
Nov 19, 2021
08:00AM EST  Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, todayannounced that management will participate in three upcoming virtual investment conferences.   GlobeNewswire Inc
Nov 15, 2021
08:00AM EST  Codexis Appoints Two New Senior Leaders for Human Resources and   GlobeNewswire Inc
08:00AM EST  Codexis to Present Data Highlighting Two New Therapeutic Discovery   GlobeNewswire Inc
Nov 5, 2021
09:37AM EDT  HC Wainwright & Co. Maintains Buy on Codexis, Raises Price Target to $38   Benzinga
09:29AM EDT  Codexis Sees FY21 Sales $98M-$103M, Raises Product Sales Guidance From $59M-$63M To $63M-$66M   Benzinga
09:29AM EDT  Codexis Q3 EPS $0.03 Beats $(0.09) Estimate, Sales $36.80M Beat $28.50M Estimate   Benzinga
Nov 4, 2021
08:00AM EDT  Funding to accelerate MAIs go-to-market strategy as the enzyme engineering phase nears completion   GlobeNewswire Inc
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Nov 3, 2021
06:43PM EDT  Codexis And Nestl Health Science Initiate A Phase 1 Clinical Trial Of CDX-7108 For Exocrine Pancreatic Insufficiency   Benzinga
Oct 21, 2021
04:05PM EDT  Codexis to Report Third Quarter 2021 Financial Results on November 4   GlobeNewswire Inc
Oct 18, 2021
08:07AM EDT  Codexis, Almelo And RC2 Announce A Tri-Party Collaboration For The Enzymatic Production Of Low Cost Sitagliptin API For The Generic Market, Including A License To Codexis Enzyme Technology In India   Benzinga
08:00AM EDT  Codexis, Almelo and RC2 Announce a Tri-Party Collaboration for the   GlobeNewswire Inc
Oct 15, 2021
09:41AM EDT  HC Wainwright & Co. Maintains Buy on Codexis, Raises Price Target to $33   Benzinga
Oct 1, 2021
10:01AM EDT  Codexis, Inc. (CDXS) shares are gaining more than 23 percent on Friday morning trade, continuing an uptrend since the company revealed an amendment and extension of an agreement with Merck to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin. There were no corporate announcements on the day to impact the stock movement.   RTTNews
Sep 10, 2021
07:43AM EDT  Codexis, Merck Extend Supply Pact For Enzyme Used To Manufacture Sitagliptin   Benzinga
Sep 9, 2021
04:12PM EDT  Codexis, Merck Amend And Extend Supply Agreement For Enzyme Used In Manufacture Of Sitagliptin   Benzinga
04:05PM EDT  Codexis and Merck Amend and Extend Supply Agreement   GlobeNewswire Inc
Sep 7, 2021
04:05PM EDT  Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, todayannounced that management will participate in two upcoming virtual investment conferences.   GlobeNewswire Inc
Aug 31, 2021
11:37AM EDT  Return on Capital Employed Insights for Codexis   Benzinga
Aug 26, 2021
08:09AM EDT  The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO   Benzinga
Aug 25, 2021
04:13PM EDT  Codexis Confirms Receipt of $15M Follow-on Orders for Proprietary Enzyme Product from Undisclosed Global Pharmaceutical Company   Benzinga
04:05PM EDT  Codexis Confirms Receipt of Follow-on Orders for Proprietary   GlobeNewswire Inc
Aug 10, 2021
02:42PM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Aug 6, 2021
06:33AM EDT  HC Wainwright & Co. Maintains Buy on Codexis, Raises Price Target to $28   Benzinga
Aug 5, 2021
05:48PM EDT  Codexis Q2 EPS $(0.07) Beats $(0.17) Estimate, Sales $25.45M Beat $18.09M Estimate   Benzinga
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 2, 2021
08:14AM EDT  Codexis Reports Expanded Collaboration With Kalsec, Entered Exclusive Supply Deal For Novel Enzyme To Produce Kalsec's Newest Natural Hop Acid, No Terms Disclosed   Benzinga
08:09AM EDT  Codexis, Kalsec Announce Expanded Collaboration For Supply Of Novel Enzyme To Sustainably Produce Natural Clean-Label Beverage Ingredient; Terms Not Disclosed   Benzinga
08:00AM EDT  Codexis and Kalsec Announce Expanded Collaboration for Supply of   GlobeNewswire Inc
Jul 26, 2021
04:07PM EDT  Codexis Reports Expansion Of Collab With Kalsec For Supply Of Novel Enzyme To Sustainably Produce Natural Clean-Label Beverage Ingreident   Benzinga
04:05PM EDT  Codexis and Kalsec Announce Expanded Collaboration for Supply of   GlobeNewswire Inc
Jul 22, 2021
04:05PM EDT  Codexis to Report Second Quarter 2021 Financial Results on August 5   GlobeNewswire Inc
Jul 14, 2021
04:07PM EDT  Codexis Announces Completion of CodeEvolver License   GlobeNewswire Inc
04:05PM EDT  Codexis Announces Completion of CodeEvolver License Technology Transfer with Global Pharmaceutical Leader   Benzinga
Jul 7, 2021
04:07PM EDT  Codexis Says Earns Milestone Payment From GlaxoSmithKline   Benzinga
04:05PM EDT  Codexis Earns Milestone Payment from GlaxoSmithKline   GlobeNewswire Inc
Jun 18, 2021
07:46AM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
07:13AM EDT  Codexis Raises 2021 Revenue Outlook After New Order For Its Enzyme Product   Benzinga
06:08AM EDT  HC Wainwright & Co. Maintains Buy on Codexis, Raises Price Target to $27   Benzinga
Jun 17, 2021
04:45PM EDT  Codexis Raises Guidance Following Receipt Of Binding Purchase Order For Up To $13.9M   Benzinga
04:45PM EDT  UPDATE: Codexis Raises FY21 Sales Guidance From $82M-$85M To $89M-$93M vs $83.7M Estimate   Benzinga
04:44PM EDT  Codexis Raises Guidance   Benzinga
04:44PM EDT  Codexis Raises 2021 Guidance Following Receipt of Significant New   GlobeNewswire Inc
Jun 10, 2021
07:04AM EDT  Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder   Benzinga
07:00AM EDT  Codexis and Takeda Expand Strategic Collaboration and License   GlobeNewswire Inc
May 25, 2021
04:05PM EDT  Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company, todayannounced that management will participate in three upcoming virtual investment conferences.   GlobeNewswire Inc
May 7, 2021
02:37PM EDT  Codexis shares were trading higher after the company reported better-than-expected Q1 EPS and sales results.   Benzinga
May 6, 2021
05:14PM EDT  Codexis Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $18.03M Beat $14.84M Estimate   Benzinga
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
Apr 22, 2021
04:05PM EDT  Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2021 on Thursday, May 6, 2021, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Companys financial results and provide a business update.   GlobeNewswire Inc
Apr 12, 2021
11:32AM EDT  Codexis shares were trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and a price target of $32 per share.   Benzinga
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2021   Benzinga
06:00AM EDT  Piper Sandler Initiates Coverage On Codexis with Overweight Rating, Announces Price Target of $32   Benzinga
Mar 1, 2021
10:14AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021   Benzinga
08:13AM EST  Stifel Initiates Coverage On Codexis with Buy Rating, Announces Price Target of $30   Benzinga
Feb 26, 2021
07:03AM EST  HC Wainwright & Co. Maintains Buy on Codexis, Raises Price Target to $26   Benzinga
Feb 25, 2021
04:55PM EST  Codexis: Q4 Earnings Insights   Benzinga
04:51PM EST  Codexis Sees FY21 Sales $82M-$85M vs $80.53M Est.   Benzinga
04:51PM EST  Codexis Q4 EPS $(0.06) Beats $(0.12) Estimate, Sales $21.03M Beat $20.88M Estimate   Benzinga
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 18, 2021
04:05PM EST  Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will present at three upcoming virtual investment conferences.   GlobeNewswire Inc
Feb 11, 2021
04:05PM EST  Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Companys financial results and provide a business update.   GlobeNewswire Inc
Feb 9, 2021
04:05PM EST  Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, announced today it will be expanding its operations into a new 36,000 square foot facility in San Carlos, CA under a ten year lease. This facility will provide space for additional research and development laboratories and related office space.   GlobeNewswire Inc
Feb 3, 2021
04:05PM EST  Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors.   GlobeNewswire Inc
Jan 28, 2021
07:28PM EST  CORRECTION: Cathie Wood's ARK Invests' Stock Purchases For Thursday, Jan. 28, 2021: RPTX, ACCD, CDXS, IONS, NVS, FATE, TSLA, EXPC, TER, SKLZ   Benzinga
Jan 13, 2021
07:00AM EST  Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Tate & Lyle (LSE: TATE.L), a leading global provider of food ingredients and solutions, have extended and deepened their relationship to enhance the production of two of Tate & Lyles newest sweeteners: DOLCIA PRIMA Allulose and TASTEVA M Stevia Sweetener.   GlobeNewswire Inc
Jan 5, 2021
07:00AM EST  Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that John Nicols, the Companys President and Chief Executive officer, will participate in a fireside chat presentation at the H.C. Wainwright BioConnect 2021 Conference, being held virtually January 11-14, 2021.   GlobeNewswire Inc
Dec 17, 2020
05:26PM EST  12 Emerging Technologies To Watch In 2021   Benzinga
08:10AM EST  The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut   Benzinga
Dec 3, 2020
12:20AM EST  Codexis Reports Pricing Of Public Offering Of 4.29 Mln Shares At $17.50/Shr   RTTNews
Dec 2, 2020
11:11PM EST  Codexis Announces Pricing of Public Offering of Common Stock   GlobeNewswire Inc
04:25PM EST  Codexis Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
Nov 24, 2020
05:02PM EST  Combines Codexis R&D and commercialization platform with Casdin Capitals investment expertiseto investin and support innovative early stage life science and synthetic biologytechnology companies   GlobeNewswire Inc
Nov 9, 2020
07:00AM EST  Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate at three upcoming virtual investment conferences:   GlobeNewswire Inc
Nov 5, 2020
05:10PM EST  Codexis Q3 EPS $(0.06) Beats $(0.11) Estimate, Sales $18.40M Beat $15.97M Estimate   Benzinga
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Oct 29, 2020
07:01AM EDT  Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that it will report third quarter 2020 financial results after market close on Thursday, November 5, 2020. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.   GlobeNewswire Inc
Sep 8, 2020
07:00AM EDT  Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming virtual investment conferences:   GlobeNewswire Inc
Aug 6, 2020
04:41PM EDT  Codexis Q2 EPS $(0.07) Beats $(0.19) Estimate, Sales $15.00M Beat $11.23M Estimate   Benzinga
07:00AM EDT  Codexis Adds Dr. Jennifer L. Aaker to its Board of Directors   GlobeNewswire Inc
Jul 30, 2020
07:00AM EDT  Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2020 financial results after market close on Thursday, August 6, 2020. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC